Publications
Our data on MammaPrint® is well documented in peer reviewed journals such as Nature and NEJM:
- Gene expression profiling predicts clinical outcome of breast cancer, Laura van 't Veer et al., Nature, vol 415, 31 January 2002, 530-535
- A gene expression signature as a predictor of survival in breast cancer, Marc van de Vijver et al., New England Journal of Medicine, vol 347, no 25, 19 December 2002.
- Molecular profiling of breast cancer: clinical implications, S Cleator et al., British Journal of Cancer, vol 90, no 6, 2004.
- Molecular portraits and 70-gene prognosis signature are preserved throughout the metastatic process of breast cancer, Britta Weigelt et al., Cancer Research, 2005; 65(20): 9155-8.
- Microarray analysis and tumor classification, John Quakenbush, New England Journal of Medicine, vol 354, no 23,
8 June 2006. - On the toxicity of chemotherapy for breast cancer – the need for vigilance, John Erban et al., Journal of the National Cancer Institute, vol 98, no 16, 16 August 2006.
- Frequency and cost of chemotherapy - related serious adverse effects in a population sample of wamen with breast cancer,
- Michael Hassett et al., Journal of the National Cancer Institute, vol 98, no 16, 16 August 2006
- Validation and clinical utility of a 70-gene prognostic signature for women with a node-negative breast cancer, Marc Buyse et al., Journal of the National Cancer Institute, vol 98, no 17, 6 Sep. 2006,
- Converting a breast cancer microarray signature into a high-throughput diagnostic test, Annuska Glas et al.,BioMed Central Genomics 2006, vol 278, no 7, 30 October 2006.
- Use of 70-gene signature to predict prognosis of patients with node-negative breast cancer: a prospective community-based feasibility study (RASTER) Bueno-de-Mesquita et al., The Lancet Oncology, published online November 26, 2007